SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) December
29, 2005
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
2.02. Results of Operations and Financial Condition.
| (a) |
To
the extent applicable, the information disclosed under Item 7.01 is
incorporated herein by reference.
|
ITEM
7.01. Regulation FD Disclosures.
| (a) |
On
December 29, 2005 the Registrant issued the press release titled
“Chembio
Reports $690,000 In Purchase Orders For Its Rapid HIV Diagnostic
Tests”
included herein as Exhibit 99.1.
|
ITEM
9.01. Financial Statements and Exhibits
(c) Exhibits.
| 99.1 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date:
December 30, 2005 Chembio
Diagnostics, Inc.
By: /s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Exhibit
99.1 Press Release
PRESS
RELEASE
CHEMBIO
REPORTS $690,000 IN FOURTH QUARTER PURCHASE ORDERS FOR ITS RAPID HIV DIAGNOSTIC
TESTS
MEDFORD,
N.Y. - December 29, 2005 - Chembio Diagnostics Inc. (OTCBB:CEMI) received
purchase orders during the fourth quarter from the Brazilian government totaling
$690,000, all related to the Company’s rapid HIV tests and technologies. This
order, when combined with orders received from the Brazilian government earlier
this year, results in a 43% increase in purchase orders received from this
customer in 2005 as compared with 2004. Chembio intends to complete shipment
of
all of the items purchased by the end of this month.
The
orders from the Brazilian government are from the Oswaldo Cruz Institute
(FIOCRUZ), an affiliate of the Brazilian Ministry of Health. As previously
reported, Chembio and FIOCRUZ signed a 13 year technology transfer, supply
and
license agreement in February of 2004.
“2005
has
been an outstanding year for our Company’s international sales and marketing,
both in terms of revenues as well as establishing our business model of local
engagement”, commented Lawrence Siebert, Chembio’s President. “We are building
on our successes in Brazil in other markets, under the leadership of Avi
Pelossof, and we are beginning to see evidence that the team Avi has established
in East and West Africa will be successful in the markets that they are pursuing
in 2006.”
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc. (Chembio) possesses expertise in the development and
manufacturing of rapid test products for various infectious diseases, including
HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics,
Inc.
may actually refer to Chembio Diagnostic Systems, Inc.; the 100%-owned
subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock
Road, Medford, NY 11763.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve
risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited
to
Chembio's ability to obtain additional financing and the demand for Chembio's
products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated events.
Factors that may impact Chembio's success are more fully disclosed in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.
Contact:
Vince
Daniels/James Carbonara
The
Investor Relations Group
212-825-3210